Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BASi, NanoViricides in Tox-Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

BASi, NanoViricides in Tox-Pact

BASi to conduct studies for IND applications

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

NanoViricides has entered into an agreement with BASi to conduct drug development studies for IND applications to the FDA for its nanoviricides drug candidates against various viral diseases.
 
BASi will conduct cGLP and non-GLP studies that are designed to assess overall safety in animals receiving multiple doses of FluCide. Specific safety pharmacology studies will also be conducted to assess the effects of FluCide on cardiovascular, respiratory and central nervous systems. These studies are required for IND submission, as well as applications for clinical trials in other countries such as Australia.
 
NanoViricides anticipates that it will need very large quantities of the drug candidate for these toxicology package studies and is currently performing scale-up studies to produce the necessary quantities. Financial terms of the pact were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics